An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Slides:

Advertisements

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Advertisements

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis: Latitude does make a difference

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results Alexa B. Kimball,

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Efficacy of simvastatin in plaque psoriasis: A pilot study

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Dermatology physician extenders: A new risk factor?

Assessing adherence with phototherapy protocols

Khanh P. Thieu, BS, Harley A. Haynes, MD

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Kishore L. Jayakumar, BS, Sara S. Samimi, MD

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss Elise A. Olsen, MD, Douglas Canfield, BS Journal.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial Lauren Okon, MD, Misha Rosenbach, MD, Michael.

Cutaneous fungal infections are commonly misdiagnosed: A survey-based study Ramsin Joseph Yadgar, BS, Neal Bhatia, MD, FAAD, Adam Friedman, MD, FAAD

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Pooja H. Rambhia, BA, Ivan J. Stojanov, DMD, Joshua Arbesman, MD

Medicaid acceptance among pediatric dermatologists

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Jennifer L. Hundley, MD, Christie L

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry.

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Simple onycholysis: A diagnosis of exclusion

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Etanercept therapy in two patients with psoriasis and concomitant hepatitis C Clara De Simone, MD, Andrea Paradisi, MD, Rodolfo Capizzi, MD, Angelo Carbone,

Lip ulceration in an immunocompromised patient

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

Leprosy masquerading as lupus

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS, CCRC, Linda Spencer, RN, BSN, CCRC, Stephen Miller, MD, FAAD Journal of the American Academy of Dermatology Volume 58, Issue 4, Pages 609-616 (April 2008) DOI: 10.1016/j.jaad.2007.12.031 Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Study design. S-PGA, Scalp Physician's Global Assessment. Journal of the American Academy of Dermatology 2008 58, 609-616DOI: (10.1016/j.jaad.2007.12.031) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Patient disposition. S-PGA, Scalp Physician's Global Assessment. Journal of the American Academy of Dermatology 2008 58, 609-616DOI: (10.1016/j.jaad.2007.12.031) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Cumulative percentage of patients who scored scalp Physician's Global Assessment (S-PGA) 0 or 1, attained 75% improvement in scalp-specific modified Psoriasis Area and Severity Index (S-mPASI 75), or rated themselves as much improved by scalp Patient's Global Assessment (S-PaGA) at 6 weeks after either treatment course. Not all patients required both courses. Journal of the American Academy of Dermatology 2008 58, 609-616DOI: (10.1016/j.jaad.2007.12.031) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Condition of scalp psoriasis in patient before (A) and after (B) treatment with alefacept. Patient had scalp-specific modified Psoriasis Area and Severity Index scores of 1.5 before treatment (A) and 0.8 after treatment (B). Journal of the American Academy of Dermatology 2008 58, 609-616DOI: (10.1016/j.jaad.2007.12.031) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions